1887

Abstract

Longitudinal analysis of chronic hepatitis C virus (HCV) infection has shown that the virus has several adaptive strategies that maintain persistence and infectivity over time. We examined four serum samples from the same chronically infected HCV genotype 4a patient for the presence of IgG antibody-associated virus. RNA was isolated from antibody-associated and antibody-free virions. Subsequent to sequence analysis, 27 aa hypervariable region 1 (HVR1) peptides were used to test the humoral immune escape. We demonstrated that differential peptide binding of Fab was associated with a single amino acid change. We provide direct evidence of natural humoral immune escape by HCV within HVR1.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000447
2016-06-01
2020-01-22
Loading full text...

Full text loading...

/deliver/fulltext/jgv/97/6/1345.html?itemId=/content/journal/jgv/10.1099/jgv.0.000447&mimeType=html&fmt=ahah

References

  1. Ball J. K., Tarr A. W., McKeating J. A.. 2014; The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res105:100–111 [CrossRef][PubMed]
    [Google Scholar]
  2. Brown R. J., Juttla V. S., Tarr A. W., Finnis R., Irving W. L., Hemsley S., Flower D. R., Borrow P., Ball J. K.. 2005; Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection. J Gen Virol86:1931–1942 [CrossRef][PubMed]
    [Google Scholar]
  3. Cashman S. B., Marsden B. D., Dustin L. B.. 2014; The humoral immune response to HCV: understanding is key to vaccine development. Front Immunol5:550 [CrossRef][PubMed]
    [Google Scholar]
  4. Chung R. T., Gordon F. D., Curry M. P., Schiano T. D., Emre S., Corey K., Markmann J. F., Hertl M., Pomposelli J. J.. 2013; Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant13:1047–1054 [CrossRef][PubMed]
    [Google Scholar]
  5. Cox A. L., Mosbruger T., Mao Q., Liu Z., Wang X. H., Yang H. C., Sidney J., Sette A., Pardoll D.. 2005; Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med201:1741–1752 [CrossRef][PubMed]
    [Google Scholar]
  6. Deng Y., Guan J., Wen B., Zhu N., Chen H., Song J., Yang Y., Wang Y., Tan W.. 2013; Induction of broadly neutralising HCV antibodies in mice by integration-deficient lentiviral vector-based pseudotyped particles. PLoS One8:e62684 [CrossRef][PubMed]
    [Google Scholar]
  7. Fafi-Kremer S., Fauvelle C., Felmlee D. J., Zeisel M. B., Lepiller Q., Fofana I., Heydmann L., Stoll-Keller F., Baumert T. F.. 2012; Neutralizing antibodies and pathogenesis of hepatitis C virus infection. Viruses4:2016–2030 [CrossRef][PubMed]
    [Google Scholar]
  8. Farci P., Shimoda A., Wong D., Cabezon T., De Gioannis D., Strazzera A., Shimizu Y., Shapiro M., Alter H. J., Purcell R. H.. 1996; Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A93:15394–15399 [CrossRef][PubMed]
    [Google Scholar]
  9. Freeman A. J., Marinos G., Ffrench R. A., Lloyd A. R.. 2001; Im munopathogenesis of hepatitis C virus infection. Immunol Cell Biol79:515–536 [CrossRef][PubMed]
    [Google Scholar]
  10. Guan M., Wang W., Liu X., Tong Y., Liu Y., Ren H., Zhu S., Dubuisson J., Baumert T. F.. 2012; Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion. J Biol Chem287:35631–35645 [CrossRef][PubMed]
    [Google Scholar]
  11. Habersetzer F., Fournillier A., Dubuisson J., Rosa D., Abrignani S., Wychowski C., Nakano I., Trépo C., Desgranges C., Inchauspé G.. 1998; Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties. Virology249:32–41 [CrossRef][PubMed]
    [Google Scholar]
  12. Inchauspé G., Honnet G., Bonnefoy J. Y., Nicosia A., Strickland G. T.. 2008; Hepatitis C vaccine: supply and demand. Lancet Infect Dis8:739–740 [CrossRef][PubMed]
    [Google Scholar]
  13. Kenny-Walsh E..Irish Hepatology Research Group 1999; Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med340:1228–1233 [CrossRef][PubMed]
    [Google Scholar]
  14. Larrubia J. R., Moreno-Cubero E., Lokhande M. U., García-Garzón S., Lázaro A., Miquel J., Perna C., Sanz-de-Villalobos E.. 2014; Adaptive immune response during hepatitis C virus infection. World J Gastroenterol20:3418–3430 [CrossRef][PubMed]
    [Google Scholar]
  15. Moreau I., O'Sullivan H., Murray C., Levis J., Crosbie O., Kenny-Walsh E., Fanning L. J.. 2008; Separation of hepatitis C genotype 4a into IgG-depleted and IgG-enriched fractions reveals a unique quasispecies profile. Virol J5:103 [CrossRef][PubMed]
    [Google Scholar]
  16. Owsianka A., Clayton R. F., Loomis-Price L. D., McKeating J. A., Patel A. H.. 2001; Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol82:1877–1883 [CrossRef][PubMed]
    [Google Scholar]
  17. Palmer B. A., Moreau I., Levis J., Harty C., Crosbie O., Kenny-Walsh E., Fanning L. J.. 2012; Insertion and recombination events at hypervariable region 1 over 9.6 years of hepatitis C virus chronic infection. J Gen Virol93:2614–2624 [CrossRef][PubMed]
    [Google Scholar]
  18. Palmer B. A., Dimitrova Z., Skums P., Crosbie O., Kenny-Walsh E., Fanning L. J.. 2014; Analysis of the evolution and structure of a complex intrahost viral population in chronic hepatitis C virus mapped by ultradeep pyrosequencing. J Virol88:13709–13721 [CrossRef][PubMed]
    [Google Scholar]
  19. Quaranta M. G., Mattioli B., Vella S.. 2012; Glances in immunology of HIV and HCV Infection. Adv Virol2012:434036 [CrossRef][PubMed]
    [Google Scholar]
  20. Ray S. C., Fanning L., Wang X. H., Netski D. M., Kenny-Walsh E., Thomas D. L.. 2005; Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med201:1753–1759 [CrossRef][PubMed]
    [Google Scholar]
  21. Shimizu Y. K., Hijikata M., Iwamoto A., Alter H. J., Purcell R. H., Yoshikura H.. 1994; Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol68:1494–1500[PubMed]
    [Google Scholar]
  22. Tarr A. W., Khera T., Hueging K., Sheldon J., Steinmann E., Pietschmann T., Brown R. J.. 2015; Genetic diversity underlying the envelope glycoproteins of hepatitis C virus: structural and functional consequences and the implications for vaccine design. Viruses7:3995–4046 [CrossRef][PubMed]
    [Google Scholar]
  23. Terilli R. R., Cox A. L.. 2013; Immunity and hepatitis C: a review. Curr HIV/AIDS Rep10:51–58 [CrossRef][PubMed]
    [Google Scholar]
  24. Thimme R., Lohmann V., Weber F.. 2006; A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res69:129–141 [CrossRef][PubMed]
    [Google Scholar]
  25. Thimme R., Binder M., Bartenschlager R.. 2012; Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol Rev36:663–683 [CrossRef][PubMed]
    [Google Scholar]
  26. Zhou X., Sun P., Lucendo-Villarin B., Angus A. G., Szkolnicka D., Cameron K., Farnworth S. L., Patel A. H., Hay D. C.. 2014; Modulating innate immunity improves hepatitis C virus infection and replication in stem cell-derived hepatocytes. Stem Cell Rep3:204–214 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000447
Loading
/content/journal/jgv/10.1099/jgv.0.000447
Loading

Data & Media loading...

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error